Status:
COMPLETED
Pharmacological Regulation of Fat Transport in Metabolic Syndrome
Lead Sponsor:
The University of Western Australia
Collaborating Sponsors:
National Heart Foundation, Australia
Conditions:
Obesity
Lipid Disorders
Eligibility:
MALE
25-70 years
Phase:
PHASE4
Brief Summary
The purpose of this study is to determine whether atorvastatin and fenofibrate are effective in the treatment of lipid disorders in obese, insulin resistant subjects.
Detailed Description
Insulin resistance is a heterogeneous metabolic disorder of complex etiology. It underpins dyslipoproteinemia, a key feature of the metabolic syndrome (MetS) that independently predicts cardiovascular...
Eligibility Criteria
Inclusion
- any three of the followings
- waist circumference \>102cm
- triglycerides \>1.7 mmol/L
- HDL-cholesterol \<1.05 mmol/L
- blood glucose \>6.1 mmol/L
- blood pressure \>130/85mmHg
Exclusion
- plasma cholesterol \>7mmo/L
- triglycerides \>4.5mmo/L
- diabetes mellitus (defined by oral glucose tolerance test)
- CVD
- consumption of \>30g alcohol/day
- use of agents affecting lipid metabolism
- APOE2/E2 genotype, macroproteinuria
- creatinaemia (\>120umol/L)
- hypothyroidism
- abnormal liver and muscle enzymes.
Key Trial Info
Start Date :
June 1 2001
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2007
Estimated Enrollment :
11 Patients enrolled
Trial Details
Trial ID
NCT00632840
Start Date
June 1 2001
End Date
December 1 2007
Last Update
March 11 2008
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.